p27/p16 fusion gene therapy - GPC Biotech

Drug Profile

p27/p16 fusion gene therapy - GPC Biotech

Alternative Names: AV-W9 gene therapy; CDK inhibitor gene therapy - GPC Biotech; Cyclin dependent kinase inhibitor gene therapy - GPC Biotech; p16/27 gene therapy; p27/p16 gene therapy

Latest Information Update: 27 Apr 2004

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GPC Biotech Inc
  • Class
  • Mechanism of Action Cyclin-dependent kinase inhibitors; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer; Vascular restenosis

Most Recent Events

  • 27 Apr 2004 Discontinued - Preclinical for Cancer in USA (unspecified route)
  • 27 Apr 2004 Discontinued - Preclinical for Vascular restenosis in USA (unspecified route)
  • 14 Nov 2002 p27/p16 gene therapy is available for licensing from GPC Biotech (www.gpc-boiotech.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top